Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.
The Medicare Payment Advisory Commission (MedPAC) voted 16-0 to recommend that Congress direct the U.S. Health and Human Services (HHS) Secretary to change how certain high cost drugs are classified for Part B payment purposes under the hospital Outpatient Prospective Payment System (OPPS).
Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
